Should we focus on novel risk markers and screening tests to better predict and prevent cardiovascular disease?

Jonathan R. Enriquez, James A de Lemos

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Editor's Note: The following Point/Counterpoint articles were derived from a debate presentation sponsored by the American Society for Preventive Cardiology at the March 2010 meeting of the American Heart Association Council on Epidemiology and Prevention, titled " Should We Focus on Novel Risk Marker and Screening Tests to Better Predict and Prevent Cardiovascular Disease?" Dr. James de Lemos presented the pro side, titled " Novel Risk Markers and Screening Tests Will Improve the Prediction and Prevention of Cardiovascular Disease," and Dr. Donald Lloyd-Jones advocated the con side, titled " Better Implementation of Existing Knowledge Will Save More Lives Than All of the Novel Biomarkers in the World." The following articles include points from the debate, rebuttal, and questions raised by the audience. We thank all authors for sharing this debate with the readership.

Original languageEnglish (US)
Pages (from-to)152-159
Number of pages8
JournalPreventive Cardiology
Volume13
Issue number4
DOIs
StatePublished - Sep 2010

Fingerprint

Cardiovascular Diseases
Cardiology
Epidemiology
Biomarkers

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Public Health, Environmental and Occupational Health

Cite this

Should we focus on novel risk markers and screening tests to better predict and prevent cardiovascular disease? / Enriquez, Jonathan R.; de Lemos, James A.

In: Preventive Cardiology, Vol. 13, No. 4, 09.2010, p. 152-159.

Research output: Contribution to journalArticle

@article{a135bca9ad4f4373940b117f4d0e552a,
title = "Should we focus on novel risk markers and screening tests to better predict and prevent cardiovascular disease?",
abstract = "Editor's Note: The following Point/Counterpoint articles were derived from a debate presentation sponsored by the American Society for Preventive Cardiology at the March 2010 meeting of the American Heart Association Council on Epidemiology and Prevention, titled {"} Should We Focus on Novel Risk Marker and Screening Tests to Better Predict and Prevent Cardiovascular Disease?{"} Dr. James de Lemos presented the pro side, titled {"} Novel Risk Markers and Screening Tests Will Improve the Prediction and Prevention of Cardiovascular Disease,{"} and Dr. Donald Lloyd-Jones advocated the con side, titled {"} Better Implementation of Existing Knowledge Will Save More Lives Than All of the Novel Biomarkers in the World.{"} The following articles include points from the debate, rebuttal, and questions raised by the audience. We thank all authors for sharing this debate with the readership.",
author = "Enriquez, {Jonathan R.} and {de Lemos}, {James A}",
year = "2010",
month = "9",
doi = "10.1111/j.1751-7141.2010.00080.x",
language = "English (US)",
volume = "13",
pages = "152--159",
journal = "Preventive Cardiology",
issn = "1520-037X",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Should we focus on novel risk markers and screening tests to better predict and prevent cardiovascular disease?

AU - Enriquez, Jonathan R.

AU - de Lemos, James A

PY - 2010/9

Y1 - 2010/9

N2 - Editor's Note: The following Point/Counterpoint articles were derived from a debate presentation sponsored by the American Society for Preventive Cardiology at the March 2010 meeting of the American Heart Association Council on Epidemiology and Prevention, titled " Should We Focus on Novel Risk Marker and Screening Tests to Better Predict and Prevent Cardiovascular Disease?" Dr. James de Lemos presented the pro side, titled " Novel Risk Markers and Screening Tests Will Improve the Prediction and Prevention of Cardiovascular Disease," and Dr. Donald Lloyd-Jones advocated the con side, titled " Better Implementation of Existing Knowledge Will Save More Lives Than All of the Novel Biomarkers in the World." The following articles include points from the debate, rebuttal, and questions raised by the audience. We thank all authors for sharing this debate with the readership.

AB - Editor's Note: The following Point/Counterpoint articles were derived from a debate presentation sponsored by the American Society for Preventive Cardiology at the March 2010 meeting of the American Heart Association Council on Epidemiology and Prevention, titled " Should We Focus on Novel Risk Marker and Screening Tests to Better Predict and Prevent Cardiovascular Disease?" Dr. James de Lemos presented the pro side, titled " Novel Risk Markers and Screening Tests Will Improve the Prediction and Prevention of Cardiovascular Disease," and Dr. Donald Lloyd-Jones advocated the con side, titled " Better Implementation of Existing Knowledge Will Save More Lives Than All of the Novel Biomarkers in the World." The following articles include points from the debate, rebuttal, and questions raised by the audience. We thank all authors for sharing this debate with the readership.

UR - http://www.scopus.com/inward/record.url?scp=77957161037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957161037&partnerID=8YFLogxK

U2 - 10.1111/j.1751-7141.2010.00080.x

DO - 10.1111/j.1751-7141.2010.00080.x

M3 - Article

VL - 13

SP - 152

EP - 159

JO - Preventive Cardiology

JF - Preventive Cardiology

SN - 1520-037X

IS - 4

ER -